Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

University of Louisville (UOFL)

Status and phase

Enrolling

Phase 2

Conditions

Pancreatic Adenocarcinoma

Treatments

Drug: Nivolumab

Procedure: Irreversible Electroporation

Study type

Interventional

Funder types

Other

Identifiers

NCT03080974

16.1190

Details and patient eligibility

About

Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

Full description

Immunotherapy and irreversible electroporation in the treatment of advanced pancreatic adenocarcinoma. This is a Phase II study in which all patients undergoing irreversible electroporation of locally advanced pancreatic adenocarcinoma will be treated with nivolumab post-operatively.

Enrollment

10 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

≥ 18 years if age
Diagnosed with stage III pancreatic cancer
Tumor is measurable
Glomerular Filtration Rate > 60 m/L/min/1.73 m(2)
Willing and able to comply with the protocol requirements
Able to comprehend and have signed the informed consent to participate

Exclusion criteria

Participating in another clinical trial for the treatment of cancer at time of screening
Are pregnant or currently breast feeding
Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure
Have non-removable implants with metal parts within 1 cm of the target lesion
Had a myocardial infarction within 3 months prior to enrollment